New Crown Antigen Detection industry concept stocks are Wanfu Bio, Qianhong Pharmaceuticals and Haili Bio.
Haili Bio: the company's first quarter 2021 total revenue of 101 million, earnings per share of 0.0210 yuan.
Haili biological wholly owned subsidiary products new crown antigen detection kit (colloidal gold method) to obtain the European Union CE access qualification.
June 30 intraday news, Haili biological shares fell 1.06% in 5 days, up 16.27% this year, the latest 14.89 yuan, down 1.13%, the price-earnings ratio of 1,517.
Thousands of red pharmaceuticals: the company's 2021 Total revenue for the first quarter was $391 million, with a gross margin of 44.56 percent and earnings per share of $0.0400.
Thousand Red Pharmaceuticals said on the interactive platform, the company's holding subsidiary Jinghong Biotechnology specializes in the research and development and production of molecular diagnostic reagents, and currently the self-developed new crown antigen detection reagents have been on the Ministry of Commerce white list of anti-epidemic material exports and began sales. In addition, the new crown nucleic acid detection kit and the fusion antibody detection reagent used to determine the effectiveness of the new crown vaccination is also in the process of development.
June 30, 2021 morning news, thousand red pharmaceuticals latest quoted 4.08 yuan, up 0.49%, 3 days the stock price fell 0.49%; this year's gains fell -4.68%, price-earnings ratio of -37.
Wanfu biological: the company's first quarter 2021 total revenue of 697 million, earnings per share of 0.4600 yuan.
Wanfu Bio: 2020 net profit is expected to be 580 million-660 million yuan, a year-on-year increase of 50%-70%. Driven by the continuous demand for new crown detection products in domestic and overseas markets, the company's new crown antibody detection reagents and new crown antigen detection reagents have realized a rapid climb in sales, which will bring strong impetus to the company's performance growth in 2020.
Wanfu biological (300482) rose 1.22% to 63.68 yuan, turnover of 28.743 million yuan, turnover rate of 0.14%, amplitude of 0.890%.
The data selected in this article is for reference only, and does not fully and accurately reflect the future of any one enterprise, and does not constitute investment advice, according to which the operation is at your own risk.